Clover Health is trading 4.05% down at $4.50 in pre-market; available reporting identifies no clear catalyst. - The company reported third-quarter revenue of $759.3 million and raised the low end of its 2026 guidance, including its net-income and Adjusted EBITDA outlook. - Results were released after the November 4 close; one report said shares were flat immediately afterward, so evidence does not establish earnings caused the November 5 decline. Market context is mixed and does not clearly explain the move.